Valuation: Corcept Therapeutics Incorporated

Market Cap 8.77B 7.84B 7.18B 6.54B 12.26B 832B 12.53B 85.7B 34.6B 438B 32.9B 32.21B 1,384B P/E 2026 *
39.8x
P/E 2027 * 19.7x
Enterprise Value 8.77B 7.84B 7.18B 6.54B 12.26B 832B 12.53B 85.7B 34.6B 438B 32.9B 32.21B 1,384B EV / Sales 2026 *
7.65x
EV / Sales 2027 * 5.23x
Free-Float
65.89%
Yield 2026 *
-
Yield 2027 * -
1 day-0.81%
1 week-6.29%
Current month-0.81%
1 month-29.44%
3 months-29.72%
6 months+56.48%
Current year+131.21%
1 week 79.4
Extreme 79.395
88.59
1 month 79.4
Extreme 79.395
122.81
Current year 28.66
Extreme 28.6601
126.38
1 year 28.66
Extreme 28.6601
126.38
3 years 20.84
Extreme 20.84
126.38
5 years 15.82
Extreme 15.825
126.38
10 years 6.7
Extreme 6.7
126.38
Manager TitleAgeSince
Chief Executive Officer 68 31/12/1998
Director of Finance/CFO 49 28/02/2021
Chief Tech/Sci/R&D Officer 48 31/01/2024
Director TitleAgeSince
Director/Board Member 68 31/12/1998
Chairman 82 31/12/1998
Director/Board Member 71 30/06/2004
Date Insider Type Main position Quantity % Market Cap. Importance
15/10/26 Sell

Chairman

-10,000 0.0093%
02/10/26 Exercice

See Remarks

73,761 0.0682%
02/10/26 Exercice

Chief Technology Officer

27,570 0.0255%
Change 5-day change 1-year change 3-year change Capi.($)
-0.81%-6.29%+9.51%+186.44% 8.77B
-0.46%+10.80%+63.52%+154.48% 1,263B
-0.97%+2.56%+43.25%+81.96% 658B
-2.05%+1.12%+32.47%+102.74% 521B
-1.54%+1.61%+53.42%+67.10% 391B
-0.78%+2.13%+72.55%+44.25% 369B
-1.69%+2.75%+32.49%+54.35% 307B
-0.72%+8.08%+11.15%+34.09% 290B
-0.12%+5.96%+55.97%+78.44% 252B
-0.21%+9.16%+42.19%+112.41% 212B
Average -0.73%+4.76%+41.65%+91.63% 427.07B
Weighted average by Cap. -0.72%+6.57%+49.07%+97.60%

Financials

2026 *2027 *
Net sales 1.15B 1.02B 938M 855M 1.6B 109B 1.64B 11.2B 4.52B 57.27B 4.3B 4.21B 181B 1.68B 1.5B 1.37B 1.25B 2.34B 159B 2.4B 16.38B 6.61B 83.75B 6.29B 6.16B 265B
Net income 242M 216M 198M 180M 338M 22.92B 345M 2.36B 953M 12.07B 906M 887M 38.13B 568M 508M 465M 424M 795M 53.94B 812M 5.56B 2.24B 28.4B 2.13B 2.09B 89.75B
Net Debt - -
Projected Income Statement - Annual - Corcept Therapeutics Incorporated
Logo Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. It is also conducting advanced clinical trials in patients with solid tumors, Amyotrophic Lateral Sclerosis (ALS) and liver disease. It operates through the discovery, development and commercialization of the pharmaceutical products segment. It sells Korlym and a generic version of Korlym in the United States using sales representatives to call on physicians caring for patients with hypercortisolism (Cushing’s syndrome). The Company's portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. It sells and distributes Lifyorli in the United States. It is developing its proprietary, selective cortisol modulator, relacorilant, as a treatment for patients with hypercortisolism.
Employees
730
Date Price Change Volume
02/11/26 US$80.46 -0.81% 1,591,464
30/10/26 US$81.12 -5.62% 1,429,163
29/10/26 US$85.95 -0.38% 1,185,785
28/10/26 US$86.28 -1.50% 1,048,071
27/10/26 US$87.59 +0.53% 925,519
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Corcept Therapeutics Incorporated
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
80.46USD
Average target price
141.00USD
Spread / Average Target
+75.24%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Corcept Therapeutics Incorporated
  1. Stock Market
  2. Stocks
  3. CORT Stock